Results 161 to 170 of about 73,125 (286)

Harnessing viral footprints in circulating free DNA (cfDNA) for early cancer detection: A focus on liquid‐biopsy‐based screening

open access: yesInternational Journal of Cancer, Volume 158, Issue 3, Page 511-526, 1 February 2026.
Abstract Viral infections play a significant role in cancer development, making detecting viral signatures a promising approach for early cancer diagnosis. Circulating free DNA (cfDNA), released into the bloodstream by tumors and other cells, has emerged as a powerful biomarker for non‐invasive cancer screening.
Richard Donkor Amponsah   +4 more
wiley   +1 more source

Tumor Immunotherapy and Microbiome: From Bench‐to‐Bedside Applications

open access: yesMedComm, Volume 7, Issue 2, February 2026.
The microbiome is related to the efficacy of immunotherapy and can be utilized to predict the efficacy and adverse reactions of immunotherapy. Microbiome‐targeted intervention strategies can improve the efficacy of ICI, but necessitating more comprehensive exploration.
Anqi Lin   +12 more
wiley   +1 more source

Inflammation and Cancer: Molecular Mechanisms and Therapeutic Targets

open access: yesMedComm, Volume 7, Issue 2, February 2026.
Chronic inflammation fuels tumorigenesis via “internal drivers” and “external attractions.” Targeting these core mechanisms with combined therapies/novel deliveries enables precise, potent anti‐inflammatory–antitumor treatment. ABSTRACT Inflammation is a core pathological factor regulating tumor initiation, progression, and therapeutic resistance, and ...
Xiaodie Liu   +4 more
wiley   +1 more source

Progress in RNA‐Targeted Therapeutics for Human Diseases

open access: yesMedComm, Volume 7, Issue 2, February 2026.
RNA‐targeted therapies are revolutionizing molecular medicine by transitioning from a “protein‐centric” focus to an “RNA‐regulatory network” approach. Leveraging RNA's diverse roles in gene regulation, signaling, and epigenetic modifications, advanced platforms such as ASOs, siRNA, miRNA, mRNA, aptamers, shRNA, and CRISPR/Cas systems are enabling ...
Wangzheqi Zhang   +10 more
wiley   +1 more source

A small molecule iCDM-34 identified by in silico screening suppresses HBV DNA through activation of aryl hydrocarbon receptor. [PDF]

open access: yesCell Death Discov, 2023
Furutani Y   +25 more
europepmc   +1 more source

IKAROS Associated Immunodeficiency and Thrombotic Thrombocytopenic Purpura

open access: yesPediatric Blood &Cancer, Volume 73, Issue 2, February 2026.
ABSTRACT Pathogenic variants in IKZF1 (IKAROS) are linked to immunodeficiency, malignancy, and immune dysregulation. We describe a family with a rare IKZF1 variant presenting with humoral immunodeficiency and thrombotic thrombocytopenic purpura (TTP). A non‐consanguineous family was clinically monitored; clinical, immunological, and genetic data (exome
Ilia Spivak   +7 more
wiley   +1 more source

A single-cell digital PCR method tailored for quantification of HBV DNA positive cells in liver biopsy tissues. [PDF]

open access: yesJ Transl Med
Li J   +9 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy